SEATTLE and MILAN, October 9, 2010 /PRNewswire/ -- Dendreon Corporation today announced the following data presentations taking place at the 35th European Society for Medical Oncology (ESMO) congress in Milan, Italy:
- Saturday, October 9, 2010, 13:00 - 14:00 CEST - Integrated Safety Results from 4 Randomized, Double-blind, Placebo-controlled Studies of Sipuleucel-T. Poster presentation. - Monday, October 11, 2010, 12:30 - 13:30 CEST - Survival Results of the IMPACT Trial of Sipuleucel-T for Advanced Prostate Cancer. Poster discussion. - Monday, October 11, 2010, 12:30 - 13:30 CEST - Results from Two Phase 1 Trials of Her2/Neu Directed Active Cellular Immunotherapy in Patients Advanced Malignancies. Poster discussion.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, sipuleucel-T (marketed in the U.S. as PROVENGE(R)), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
SOURCE: Dendreon Corporation
CONTACT: Katherine Stueland, Vice President, Corporate Communications andInvestor Relations, +1-206-829-1522, email@example.com